Vaccination against cutaneous and mucosal papillomavirus in cattle.
Viruses are responsible for approximately 15% of human cancer worldwide. Human papillomavirus and hepatitis B virus are the recognized agents of cervical and liver cancer, respectively, which together constitute 80% of all virally induced cancers. If measures could be found to bring viral infection under control, a great proportion of human cancer would be greatly reduced. Experimental vaccines are being developed against papillomavirus. In principle two different types of vaccine can be envisaged: prophylactic vaccines that would elicit virus-neutralizing antibodies and would prevent infection and therapeutic vaccines that would induce regression of established lesions before progression to malignancy took place. The research on vaccines against human papillomavirus is hampered by the difficulties encountered in growing the virus in tissue culture and by the unacceptable nature of experimentation in humans. Effective vaccines, both natural and genetically engineered, have been developed against bovine papillomavirus and cottontail rabbit papillomavirus. The success obtained with the animal models supports the optimistic prediction that in the relatively near future vaccines will be available against the most problematic or potentially dangerous forms of papillomatosis in humans.
Campo
M S
MS
Beatson Institute for Cancer Research, CRC Beatson Laboratories, Glasgow, UK.
Jarrett
W F
WF
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D004947:Esophagus; D005753:Gastric Mucosa / Q000821:virology; D006801:Humans; D009092:Mucous Membrane / Q000821:virology; D030361:Papillomavirus Infections / Q000517:prevention & control / Q000662:veterinary*; D012874:Skin Diseases, Infectious / Q000517:prevention & control / Q000662:veterinary*; D014412:Tumor Virus Infections / Q000517:prevention & control / Q000662:veterinary*; D014765:Viral Vaccines / Q000627:therapeutic use*
D014765:Viral Vaccines